Thelansis

Uveal Melanoma (UM) Market Outlook Thelansis’s “Uveal Melanoma (UM) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Uveal Melanoma (UM) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest impact on the market’s trajectory? What...

Uveal Melanoma (UM) Market Outlook Thelansis’s “Uveal Melanoma (UM) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Uveal Melanoma (UM)   treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Uveal Melanoma (UM) Overview Uveal melanoma (UM), also known as ocular melanoma, is the most common primary malignancy of the eye in adults, yet remains a rare disease, comprising only a small percentage of all melanoma cases. This cancer originates from the pigment-producing cells within the uveal tract—the iris, ciliary body, and most frequently, the choroid—and is biologically distinct from skin melanoma, showing poor response to standard sy...

 Ocular melanoma, a type of cancer that originates in the pigment-producing cells of the eye or surrounding area, is a relatively uncommon condition. The two subtypes of ocular melanoma are the uveal and conjunctival forms, which display notable differences. The presentation of ocular melanoma can vary depending on its location and may manifest as symptoms such as blurred vision, reduced visual field, flashing lights, redness, discomfort, pain, or a sensation of pressure. Several risk factors for the development of ocular melanoma have been identified, including fair skin, atypical skin moles, light eye color, iris moles, freckles, and exposure to sun or tanning, as well as a genetic correlation at the CLPTM1L locus between uveal and cutaneous melanoma. The primary mechanisms underlying the development of ocular melanoma may involve oxidative damage to pigmented tissues and genetic alterations resulting from adenine-to-cytosine mutations in uveal melanoma or adenine-to-thymine muta...

 Uveal melanoma (UM) is a rare malignancy that originates from melanocytes within the uveal tract of the eye. Uveal melanoma represents ∼ 85% of all ocular melanomas, and up to 50% of patients develop metastatic disease. Metastases are most frequently localized to the liver, and few patients are candidates for potentially curative surgery associated with a poor prognosis. Uveal melanoma (UM) has a high tendency to metastasize, resulting in high mortality. The common sites of metastasis include the liver (89%), lung (29%), and bone (17%). UM is adults' most common primary intraocular malignancy, representing 3%–5% of all melanomas. UM most commonly arises from choroidal melanocytes (85%–90%) but can also arise from the iris (3%–5%) and ciliary body (5%–8%). ·        The incidence of uveal melanoma ranges from 5.1 to 6.3 per million population in the USA. Thelansis’s “Uveal Melanoma (UM) Market Outlook, Epidemiology, Competitive Landscape , and Marke...